ANB 004 - Biocad
Alternative Names: ANB-004 - BiocadLatest Information Update: 02 Mar 2023
At a glance
- Originator Biocad
- Class Spinal muscular atrophy gene therapies
- Mechanism of Action Gene transference; Survival of motor neuron 1 protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Spinal muscular atrophy
Most Recent Events
- 28 Feb 2023 Phase-I/II clinical trials in Spinal muscular atrophy (In infants, In neonates) in Russia (IV) (NCT05747261)
- 01 Aug 2022 ANB 004 - Biocad is available for licensing as of 01 Aug 2022. https://biocadglobal.com/partnering
- 01 Aug 2022 Preclinical trials in Spinal muscular atrophy in Russia (IV) (Biocad pipeline, August 2022)